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MaThe role of imaging in the diagnosis of valvular heart disease is well established through years of investigation and
validation. However, the role of imaging in guiding the treatment decision-making for valvular heart disease is less well
established, and there is a striking paucity of randomized trial data to help inform these decisions. Given this relative
absence of randomized trial data, the present article highlights some of the most important knowledge gaps and defines
meaningful opportunities for the field to help advance the care of patients with valvular heart disease in a cost-effective
fashion. (The PARTNER 3-Trial: The Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk
Patients With Aortic Stenosis [P3]; NCT02675114; Medtronic Transcatheter Aortic Valve Replacement in Low Risk Pa-
tients; NCT02701283) (J Am Coll Cardiol Img 2017;10:286–95) © 2017 by the American College of Cardiology
Foundation.R andomized controlled trials represent thehighest quality data afforded to clinicians tohelp inform downstream decision-making.
Recently, there has been an explosion of new pro-
spective randomized trials that have been structured
to define the role of anatomic and functional testing
for the evaluation of coronary artery disease in pa-
tients with stable chest pain (1–4). However, in the
arena of structural heart diseases such as valvular
heart disease, the role of noninvasive imaging in
downstream decision-making has largely been based
on observational data; there are few randomized trial
data available, despite the very well-established role
for such data in the diagnosis of valvular pathologies
validated over decades against invasive assessment
(5,6). It is particularly noteworthy that although
consensus exists that imaging helps support patient
management, there are few comparative effective-
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Although there may seem to be a deficit of data, the
very supportive nature that noninvasive imaging
plays in transcatheter valvular interventions does not
lend itself to randomization. The focus is the optimi-
zation of procedural outcomes, and the imaging
needed to facilitate this focus varies based on site
expertise and the evolution of the technology. Despite
the lack of randomized trials affirming the clinical
utility of imaging in valvular heart disease, imaging is
increasingly being used to assess pre-procedural risk,
as well as for the assessment of procedural success
as core laboratory–adjudicated endpoints in large
interventional transcatheter valvular trials. The pre-
sent study thus highlights the evolving role of
noninvasive imaging for pre-procedural planning in
transcatheter valvular interventions and also as an
endpoint in clinical trials. In doing so, our aim was toValve Innovation, University of British Columbia,
eiden, the Netherlands; and the cPiedmont Medical
ards Lifesciences, Circle Cardiovascular Imaging,
mography core laboratory services from Edwards
options for HeartFlow and Circle Cardiovascular
r. Blanke has served as a consultant for Edwards
rtFlow; and has received institutional support for
, Medtronic, Neovasc, Tendyne, and GDS. All other
ents of this paper to disclose. Pamela Douglas, MD,
ber 19, 2016, accepted September 22, 2016.
AB BR E V I A T I O N S
AND ACRONYM S
CMR = cardiac magnetic
resonance
CT = computed tomography
CTA = computed tomography
angiography
ICA = invasive coronary
angiography




MR = mitral regurgitation








THV = transcatheter heart
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287emphasize the important supportive role imaging
plays in transcatheter valvular interventions, as
endpoints in valvular heart disease intervention tri-
als, and finally the potential outstanding questions
regarding imaging in valvular disease that may lend
themselves to be answered through randomized
clinical trials (Central Illustration).
IMAGING TO SUPPORT PRE-PROCEDURAL
PLANNING FOR TRANSCATHETER
VALVULAR INTERVENTIONS
With surgical valvular interventions, there is little
need for additional imaging to aid in procedural
planning in advance of the procedure. However, with
the advent of transcatheter valvular interventions,
the requirement to evaluate device landing zones and
valvular structures became acutely apparent in a way
previously not needed. Until then, the aortic annulus
was a less well-defined anatomic entity, at least from
an imaging perspective, because previously it was
not relevant to guide any surgical device selection.
As it became apparent that the sex of the patient was
not enough to help inform device selection and
sizing, the field changed its focus toward imaging to
help inform the procedure and improve clinical
outcomes.
With this increased focus came more thoughtful
and thorough investigation, which quickly highlighted
that even traditional 2-dimensional echocardiographic
measurements were not sufficient to comprehensi-
vely assess the noncircular anatomy. Consistently,
3-dimensional multidetector computed tomography
(MDCT) scanning and transesophageal echocardiog-
raphy (TEE) have been shown to enhance annular
assessment and enable more effective device selection
that has facilitated an improvement in clinical out-
comes (5–7). In particular, a steady reduction has
occurred in the extent and frequency of paravalvular
regurgitation (PAR), as well as annular injury and cor-
onary occlusion, mainly due to a better understanding
of anatomic risk, ultimately allowing for more
informed and individualized procedural planning.
Through imaging, many of the historical myths
regarding cardiac anatomy have been dispelled. It was
assumed, until recently, that the aortic annulus was
round. In 2008, the elliptical geometric nature of the
aortic annulus was discovered by using MDCT studies,
with significant differences between the short- and
long-axis annular dimensions (8), which makes gran-
ular device sizing on the basis of 2-dimensional im-
aging more or less impossible. The rates of moderate
or greater paravalvular aortic regurgitation (PAR) in
the early trial experiences were 12.2% and 10% in thePARTNER (Placement of Aortic Transcatheter
Valves) IA and US CoreValve Pivotal Study
transcatheter aortic valve replacement
(TAVR) cohorts, respectively (9,10). Given
that PAR has been shown to be associated
with increased mortality in multiple ran-
domized trial subanalyses (11–13), procedural
modifications to prevent PAR have become a
more prominent focus. With the use of MDCT
scanning and 3-dimensional TEE, as well as
further iterations of the transcatheter heart
valves (THVs), there has been a steadily
decline in the burden of significant PAR
through more appropriate and granular de-
vice sizing (Figure 1). The recently reported
PARTNER SAPIEN 3 intermediate-risk data
showed a very low 30-day rate of moderate or
severe PAR (3.4%), which was at least in part
believed to be attributable to the systematic
use of 3-dimensional imaging for more
specific THV sizing (12–14). In addition,
the low 30-day mortality rate reflects a
reduction in major vascular complications,
life-threatening bleeding, and other acute procedural
complications such as coronary occlusion and annular
rupture. Both of these factors contributed to early
mortality in previous TAVR studies and are likely
associated with the reduced mortality seen in this
trial. The investigators surmised that in addition to
increasing operator experience, the systematic utili-
zation of MDCT scanning for vascular access and
annular sizing allowed these meaningful improve-
ments in clinical outcomes.
Building on the positive impact with TAVR, the
early experiences with transcatheter mitral valve
replacement have been enriched by the use of
advanced imaging. The segmentation of the non-
planar saddle-shaped mitral annulus has become
routine in the advanced imaging laboratories that are
supporting early feasibility trials in the transcatheter
mitral valve replacement space (Figure 2). In addition,
advanced imaging has already shed substantial light
on various potential mechanisms for left ventricular
outflow tract (LVOT) obstruction and the patterns of
ventricular remodeling unique to the different
mechanisms of mitral regurgitation (MR) (15–18).
There are a number of predisposing factors for LVOT
obstruction that relate to anatomic and device-
related issues. Importantly, significant LVOT anat-
omy variation exists owing to configuration of the
interventricular septum, left ventricular size, and
aorto-mitral angulation (19). In particular, a hyper-
trophied, bulging septum reduces the LVOT and neo-
LVOT cross-sectional areas.
valve
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relationship between device size and the extent of
ventricular protrusion and the risk of LVOT obstruc-
tion, T models of risk integrating the concept of the
neo-LVOT have become essential for patient
screening in a more granular fashion than would
be possible with planar imaging. Computed tomog-
raphy (CT) transcatheter mitral valve replacement
simulation can predict neo-LVOT geometry by
embedding either a cylindrical or cone-shaped con-
tour, or even a device-specific stereolithographic
contour, into the CT dataset; this action is then
followed by segmentation and planimetric assess-
ment of the neo-LVOT cross-sectional area. Unfortu-
nately, this virtual assessment is somewhat limited,
however, because there are no well-defined threshold
values for the neo-LVOT area yet available; this
limitation currently forces the field to default to ex-
periences from patients with hypertrophic obstruc-
tive cardiomyopathy, in whom the risk of developing
an LVOT gradient >50 mm Hg has been shown tocorrespond with LVOT area cutoffs ranging from 0.85
to 2.0 cm2 (20–23). In the early feasibility trials, it
seems reasonable to perform both MDCT scanning
and TEE. However, as the procedure evolves, there is
an opportunity to assess the true incremental value of
MDCT scanning beyond TEE, which is needed for MR
quantification, by randomizing patients to undergo
transcatheter mitral valve replacement with MDCT
and without MDCT guidance.
While the field develops an understanding on how
to use imaging to screen, select, and guide trans-
catheter mitral valve implantation, the knowledge
supporting transcatheter mitral valve repair is much
more mature. The MitraClip system (Abbott Vascular,
Minneapolis, Minnesota) has been the most
studied device used for the treatment of mitral
insufficiency. The EVEREST II (Endovascular Valve
Edge-to-Edge Repair Study) 5-year data confirmed
that the MitraClip device reduces the severity of
MR and its symptoms while promoting favorable
reverse remodeling of the left ventricle at 5 years’
FIGURE 1 Planimetric Assessment of Systolic Annular Dimensions
Representative computed tomography (CT) image analysis performed for assessment pre-transcatheter aortic valve replacement (TAVR).
Multiplanar oblique imaging is used to create an image reconstruction of the annular plane. This approach enables the image reviewer to
measure the annular (area 4.70 cm2) and perimeter (77.8 mm). LC ¼ left cusp; NC ¼ noncoronary cusp; RC ¼ right cusp.
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289post-procedure (24). Patient selection relies heavily
on high-quality echocardiographic guidance with the
key inclusion criterion being the presence of a
regurgitant jet between A2 and P2 and not between
the commissures. There are specific echocardio-
graphic measurements for functional MR (e.g., the
coaptation length must be at least 2 mm and the
coaptation depth <11 mm). For patients with a flail
leaflet, the flail gap needs to be <10 mm with a flail
width <15 mm (25). Before the discrimination of these
findings, the main and irreplaceable role of echocar-
diography is determination of the mechanism of MR
and its severity.
IMAGING AS AN ENDPOINT
OF A CLINICAL TRIAL
POST-PROCEDURAL THV ASSESSMENT. Echocardio-
graphic assessment both intraprocedurally and post-
procedurally is essential for the evaluation of THV
function (26). Intraprocedurally, with the advent of
recapturable devices, findings of increased THV gra-
dients on TEE can allow the proceduralist to reposi-
tion the valve to allow for more optimal deploymentand hemodynamics. Standardization of reporting and
grading of THV dysfunction has been a focus of the
Valve Academic Research Consortium update (27)
(Table 1). Importantly, however, the definitions and
criteria will almost certainly continue to be refined as
reports of normative values from various trans-
catheter devices become available from ongoing reg-
istries and trials.
Paravalvular regurgitation post-TAVR. With the improve-
ment in clinical outcomes after structural heart
disease interventions, investigators have pursued
endpoints beyond mortality, myocardial infarction,
and stroke. In the TAVR space, the standardization
and reproducibility of paravalvular leakage quantifi-
cation with echocardiography has been essential for
the adjudication of procedural outcomes. Invasive
measures of PAR have proven to be only modestly
reliable and to correlate weakly with downstream
clinical outcomes (10,11). Echocardiographic adjudi-
cation of PAR has evolved since its introduction into
clinical practice. Several parameters and criteria have
been proposed in the recent American Society of
Echocardiography/European Association of Cardio-
vascular Imaging and Valve Academic Research
FIGURE 2 3D Mitral Annular Segmentation on CT Scanning
(A) Saddle-shaped mitral annular segmentation as a cubic spline interpolation. (B) Pink line ¼ anterior peak; red line ¼ posterior peak (posterior mitral leaflet
insertion); green and blue dots ¼ fibrous trigones. Importantly, the anterior peak projects into the left ventricular outflow tract (short-axis view [C] and long-axis view
[D]). The more planar D-shaped annular contour is created by truncating the saddle-shaped contour at the trigone-to-trigone distance (yellow lines [E and F]).
Important measurements are the projected area septal-to-lateral (SL) and commissure to commissure (CC) distances; the latter is oriented perpendicularly to SL while
transecting through the centroid (F). Reprinted with permission from Blanke et al. (20). CT ¼ computed tomography; P. PE. ¼ posterior perimeter.
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using echocardiography. Using these criteria for
grading PAR, echocardiographic assessment post-
implantation has proven to be highly discriminatory
for downstream clinical outcomes.TABLE 1 Valve Academic Research Consortium–2 Guidelines for the D
Prosthetic Aortic Valve Stenosis* Normal
PPM Insignificant
Quantitative parameters (flow-dependent)†
Peak velocity <3 m/s
Mean gradient <20 mm Hg
Quantitative parameters (flow-independent)
Doppler velocity index $0.35
Effective orifice area, cm2 for BSA $1.6 m2 >1.1 cm2
Effective orifice area, cm2 for BSA <1.6 m2 >0.9 cm2/m2
EOA indexed (cm2/m2) for BMI <30 kg/m2 >0.85 cm2/m2
EOA indexed (cm2/m2) for BMI $30 kg/m2 >0.70 cm2/m2
BMI ¼ body mass index; BSA ¼ body surface area; EOA ¼ effective orifice area; PPM ¼Recently, Kodali et al. (13), in the largest published
single study to evaluate the impact of PAR, noted that
patients with moderate/severe PAR demonstrated, on
average, an increase in left ventricular end-diastolic
volume with less reduction in left ventricular massiagnosis of Transcatheter Valve Dysfunction (27)
Mild Stenosis Moderate–Severe Stenosis
Moderate Severe
3–4 m/s >4 m/s
20–40 mm Hg >40 mm Hg
0.35–0.25 <0.25
1.0–0.8 cm2 <0.8 cm2
0.9–0.6 cm2/m2 <0.6 cm2/m2
0.85–0.65 cm2/m2 <0.65 cm2/m2
0.90–0.60 cm2/m2 <0.60 cm2/m2
patient prosthesis mismatch.
FIGURE 3 Multiplanar CT Imaging After Self-Expanding TAVR Implantation
Volume-rendered and multiplanar-reformatted imaging of a CoreValve (Medtronic, St. Paul, Minnesota) implanted 20 days previously
showing an area of hypoattenuation at the 9 o’clock position (arrow) in keeping with subclinical thrombus formation. Abbreviations as in
Figure 1.
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291and reduced improvement in New York Heart Asso-
ciation functional class. Furthermore, both mild
and greater than mild PAR resulted in significantly
higher 1-year mortality. The impact of mild PAR on
mortality remains controversial: other studies have
not consistently found a link between mild PAR and
an increase in 1-year mortality. In the FRANCE-2
(French Aortic National CoreValve and Edwards)
registry, in which site-graded PAR was analyzed, pa-
tients with grade 1 or mild PAR did not have increased
1-year mortality compared with patients with no PAR
or trace PAR. One potential explanation for this dif-
ference is the variability in the assessment of PAR
severity (29–31).
In addition, cardiac magnetic resonance (CMR),
with its tomographic nature and lack of reliance on
echocardiographic windows, has recently been shown
to be highly valuable for the adjudication of PAR
severity. Phase contrast mapping of flow velocities
allows for the quantification of flow velocity and
volume without intravenous contrast (32,33). Ribeiro
et al. (32) recently showed that not only is CMR
reproducible but it is feasible to use in nearly all pa-
tients post-TAVR, with 97% of subjects having PARsuccessfully evaluated. In addition, and incremental
to echocardiography, CMR-graded PAR strongly pre-
dicts adverse clinical events after TAVR. While the
data are mounting and are consistent, the need for
routine clinical integration of CMR post-TAVR is
neither well established nor clear. Although seem-
ingly incremental to echocardiography, to add the
additional costs and burden, CMR will likely need to
be shown to help guide clinical decision-making post-
TAVR that helps improve clinical outcomes. Given
that interventional management of PAR is varied in
its use, a trial randomizing between post-implant
echocardiography and magnetic resonance imaging
(MRI) to guide downstream treatment decision-
making would be highly complex. This complexity
would occur more because of the lack of clarity
regarding how to best manage moderate PAR rather
than because of the difficulties of performing MRI
post-TAVR.
Leaflet thickening. Clinical valve thrombosis post-
TAVR typically manifests with symptoms of heart
failure and rising echocardiographic gradients. In a
large registry of >4,200 patients undergoing TAVR,
Latib et al. (34) documented the frequency of clinically
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median follow-up period (Figure 3). In contrast, sub-
clinical leaflet thrombus or hypoattenuating leaflet
thickening has been recently identified at a much
higher rate by using routine post-implant MDCT. The
incidence of hypoattenuating leaflet thickening has
varied across series and reports as well as across THV
platforms, ranging from 10% to 44%, and is impor-
tantly uniquely identified on CT scans (35–37). Early
follow-up studies suggest that the anatomic findings
almost certainly relate to fibrin/thrombus because
they resolve after patients are given Coumadin and are
commonly not identified in those subjects who are
receiving therapeutic anticoagulation therapy at the
time of CT scanning; however, the clinical impact of
these findings remain unclear. Importantly, there has
been only a modest indication for increased risk of
transient ischemic attacks (37) in a single study but no
indication for increased risk of stroke or struc-
tural valve degeneration. As such, post-implant MDCT
scanning has been embedded within both of
the recently initiated low-risk trials in which
patients are randomized to undergo surgery and TAVR
(NCT02675114 and NCT02701283). Importantly, this
action will represent a meaningful opportunity to
more clearly define the incidence of hypoattenuating
leaflet thickening and its clinical impact in a multi-
center approach, thereby eliminating selection
and reporting bias and mitigating the risk of
site intervention by having the CT examinations
evaluated by a single core laboratory. This step is
essential to help combat the desire to layer tests and
overimage with no clear evidence of appropriate
clinical utility (38,39).
Randomized trials evaluating the clinical utility of
imaging. Much attention has been given to defining
our understanding of how to use imaging to diagnose
and treat valvular disease. Unfortunately, less focus
has been given to the cost-effectiveness and thera-
peutic impact that imaging has on valvular disease
management. Although the realm of diagnostics may
not always enable testing to be randomized to
determine clinical utility, in a time of rising health
care costs and increasingly scarce resources, it be-
hooves us as imagers to ensure that imaging is used in
a clinically efficacious and cost-effective fashion.
QUESTIONS TO BE ANSWERED BY
POTENTIAL RANDOMIZED TRIALS
ARE ECHOCARDIOGRAPHY AND CT SCANNING
BOTH NEEDED IN ADVANCE OF TAVR? At present,
the question of whether echocardiography and CT
scanning are both needed in advance of TAVR couldundoubtedly be debated from both sides. There is a
strong push toward a minimalistic approach to TAVR
to facilitate more rapid discharge and help contain (if
not reduce) costs. Thus, many heart teams have
moved away from TEE support at the time of the
procedure to allow for conscious sedation as opposed
to general anesthesia. Although this approach seems
obvious to reduce length of stay and subsequently
reduce costs, its effectiveness remains theoretical
because it has never been proven in a prospective
randomized trial. In largely single-center studies,
there have been early successes from using mini-
malistic approaches by enabling earlier discharge and
reducing the morbidity of general anesthesia with the
use of pre-implantation CT scanning and balloon
sizing of the annulus for device selection (4,40).
Although the potential for cost savings and more
rapid discharge is real, others have shown that the
elimination of TEE is not without risk. Early experi-
ences published by Bagur et al. (41) showed that the
use of TEE significantly reduced fluoroscopic time
and the amount of intra-arterial contrast used to
assist the procedure. The FRANCE2 registry docu-
mented a higher incidence of post-procedural aortic
regurgitation in those patients who underwent TAVR
with local anesthesia without TEE support than those
with general anesthetic and TEE support. Finally, in
the Brazilian TAVR registry, the use of TEE at the time
of the procedure was associated with a reduced risk of
overall (hazard ratio: 0.57) and late (hazard ratio:
0.47) mortality (42). Given these conflicting results, it
would seem that there is equipoise between these 2
strategies that in our opinion can only be broken with
the use of a prospective randomized trial.
IS INVASIVE CORONARY ANGIOGRAPHY MANDATORY
BEFORE TAVR OR CAN A SELECTIVE INVASIVE
CORONARY ANGIOGRAPHY STRATEGY SUPPORTED BY
COMPUTED TOMOGRAPHY ANGIOGRAPHY WORK? Cor-
onary computed tomography angiography (CTA) has
established itself as the noninvasive gold standard for
the detection of and exclusion from obstructive
anatomic coronary disease compared with invasive
coronary angiography (ICA). This high diagnostic
performance, however, has been validated in patients
with stable chest pain typically in sinus rhythm,
reduced and stable resting heart rates, and supported
by the use of beta-blockade (43). Patients being eval-
uated before TAVR are much more likely to not be in
sinus rhythm, and beta-blockade is generally avoided
due to the presence of severe aortic stenosis, however
(44). Furthermore, patients are often assumed to have
a high burden of coronary artery calcification, with
anticipated low specificity of coronary findings on CT
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293scanning, given the well-known relationship of the
aortic valve calcification and coronary artery calcifi-
cation. Owing to the assumed limitations of CTA,
particularly when TAVR was introduced, CTA has
played a very limited role in the evaluation of coronary
artery disease before TAVR. This scenario is further
confounded by the fact that the management of
coronary artery disease before TAVR is not well
established.
The role of ICA before TAVR was originally to eval-
uate the extent and severity of coronary artery disease,
as well as to assess the iliofemoral access, the aortic
root angulation, and coronary ostial height and to
obtain a gross assessment of annular dimensions. Over
time, pre-TAVR CT scanning has reduced the necessity
of ICA for most of these tasks with the exception of the
evaluation of coronary artery disease, although this
scenario is also changing with the rapid technology
developments in the field of CT scanning. These de-
velopments include single-beat/whole heart coverage,
significantly improved mechanical temporal resolu-
tionwith dual-source technology, and newalgorithmic
approaches to motion correction. Thus, there is a
growing body of largely single-center data which sug-
gest that coronary CTA in the pre-TAVR population is
accurate compared with ICA (44–46).
Building on these technical and accuracy studies,
Chieffo et al. (46), in a large single-center observa-
tional cohort, have provided data which suggest that
a selective ICA strategy guided by the presence of
obstructive coronary artery disease findings accord-
ing to coronary CTA is a safe clinical approach. In 491
patients treated with TAVR, 375 (76.3%) underwent
only coronary CTA, whereas coronary CTA and ICA
were performed in 116 (21.7%) patients. The in-
vestigators noted no differences in crude major
adverse cardiovascular and cerebrovascular event
rates at 30 days and 1 year between the 2 groups. After
multivariable adjustment, coronary CTA performed
alone was not associated with a higher risk of major
adverse cardiac events at 1 year of follow-up (hazard
ratio: 0.89; 95% confidence interval: 0.49 to 1.60;
p ¼ 0.69). They also noted a shorter overall in-
hospital stay (in-hospital admission to final dis-
charge) in patients who just underwent coronary CTA
(9 [7 to 14] days vs. 10 [8 to 16] days with mandatory
ICA; p ¼ 0.04).
Despite the potential of coronary CTA to screen
patients for the presence of prognostic relevant cor-
onary artery disease and subsequently eliminate a
significant number of ICAs being performed before
TAVR, most heart teams remain appropriately hesi-
tant for a number of reasons, including the lack of
randomized trial data. A randomized trial testing thehypothesis that a coronary CTA with ad hoc coronary
angiography is noninferior to a routine combination
of coronary angiography with coronary CTA is war-
ranted; such data could help provide unbiased evi-
dence for safety, efficacy, and efficiency regarding
the use of a complete noninvasive assessment of pa-
tients referred for TAVR. This approach may also help
lead to shorter referral-to-procedure times and
possibly reduce ancillary costs related to a TAVR
procedure.
CAN MRI HELP IN THE GRADING OF THE SEVERITY
OF MR AND THE SELECTION OF PATIENTS TO
UNDERGO MITRAL VALVE INTERVENTION? Echo-
cardiography is by far the most commonly used
method for the diagnosis and grading of MR. In
patients with severe MR, American College of
Cardiology/American Heart Association guidelines
recommend surgical intervention in the setting of left
ventricular dysfunction, even in the absence of
symptoms (47–49). A more aggressive approach has
recently been advocated, with proponents arguing
that results are superior when there is earlier surgical
intervention (47–49). The clinical outcomes after
mitral valve surgery, both repair and replacement,
show improved quality of life in the setting of durable
resolution of MR and left ventricular remodeling.
Interestingly, recently published experiences by
Uretsky et al. suggest that pre-intervention MRI
adjudication of MR severity allows for the identifica-
tion of patients with severe MR who are likely to
experience left ventricular remodeling post-
intervention. In this study, there was a strong
correlation between post-surgical left ventricular
remodeling and MR severity as assessed by using MRI
(r ¼ 0.85; p < 0.0001) but no correlation between
post-surgical left ventricular remodeling and MR
severity as assessed by using echocardiography
(r ¼ 0.32; p ¼ 0.1) (45). Importantly, the agreement
between MRI and echocardiographic estimates of MR
severity was modest in the overall cohort (r ¼ 0.6;
p < 0.0001), and there was a poorer correlation in the
subset of patients sent for surgery (r ¼ 0.4; p ¼ 0.01).
The investigators suggest that the reasons for the
greater likelihood of left ventricular remodeling with
MRI identifying severe MR may relate to the over-
estimation of MR with echocardiography. These data
are not the first to show discordance between MRI
and echocardiography in terms of MR severity. This
outcome has been described repeatedly in the litera-
ture (47–49); however, this study was the first to
suggest that MRI may be more accurate through the
tighter correlation with downstream remodeling seen
in the MRI arm.
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294These interesting data call into question whether
MRI can help better identify patients who should
undergo mitral valve intervention. Historically, such
data may motivate a change in practice but to avoid
unnecessary layering of tests, it would be prudent to
perform a trial randomizing patients to undergoing
echocardiography versus MRI for the determination
of MR severity and the appropriateness of mitral
valve intervention. Without these data, and given the
years of experience using echocardiography for MR
adjudication, we must learn from past mistakes and
not rush to change practice without prospective
randomized data.
CONCLUSIONS
Current knowledge and clinical practice in the field of
imaging for valvular heart disease is supported by very
modest, if any, randomized trial data. In valvular
disease intervention, imaging plays important sup-
portive roles to help optimize clinical outcomes
and, as such, it largely does not lend itself to
randomization. Decisions regarding when and how toimage should be made on the basis of a number of
factors, including site expertise, patient factors, and
procedural expectations. Although many of the issues
may not lend themselves to randomization, there are a
number of opportunities to meaningfully advance the
field of valvular heart disease through prospective
randomized trials. Imaging has rapidly ascended to
become an essential clinical tool to aid in the diagnosis
of valvular disease and to assist procedural interven-
tion. However, we must not simply be fascinated by
improving imaging quality but constantly focus on
improving our understanding of how imaging can help
improve downstream clinical outcomes, which is, in
fact, why we image in the first place: not for a beautiful
image but to help the patients we collectively serve.
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